What oral antibiotics are recommended for treating cellulitis?

Oral Antibiotics for Cellulitis

For typical non-purulent cellulitis, use cephalexin 500 mg four times daily or dicloxacillin 500 mg four times daily for 5 days, as these β-lactam antibiotics effectively cover the usual streptococcal and methicillin-susceptible Staphylococcus aureus pathogens without requiring routine MRSA coverage. 1, 2

First-Line Oral Therapy for Non-Purulent Cellulitis

The choice of antibiotic depends on whether the cellulitis is purulent or non-purulent, as this determines the likely pathogen:

Non-Purulent Cellulitis (Most Common Presentation)

• β-lactam antibiotics are the oral agents of choice because β-hemolytic streptococci and methicillin-susceptible S. aureus cause the majority of cases 1, 3
• Recommended first-line options:
  • Cephalexin 500 mg orally four times daily 4, 1, 2
  • Dicloxacillin 500 mg orally four times daily 4, 1
  • Amoxicillin (appropriate dosing for streptococcal coverage) 1
  • Penicillin (for penicillin-susceptible streptococci) 1
• Treatment duration: 5 days is sufficient if clinical improvement occurs by day 5; extending therapy provides no additional benefit 5, 1, 2
• A prospective study demonstrated that β-lactam therapy achieved 96% clinical success in non-purulent cellulitis, confirming MRSA coverage is unnecessary in typical cases 1, 2

For Penicillin-Allergic Patients (Non-Immediate Hypersensitivity)

• Cephalexin remains appropriate unless the patient has immediate hypersensitivity reactions 4
• Clindamycin 300-450 mg orally three times daily is an alternative that covers both streptococci and MRSA 4, 1, 6

When to Add MRSA-Active Coverage

Do not routinely cover MRSA in non-purulent cellulitis. Add MRSA-active antibiotics only when specific high-risk features are present 1, 2:

Indications for MRSA Coverage:

• Lack of clinical response after 48-72 hours of β-lactam therapy 1, 2
• Purulent drainage or exudate (purulent cellulitis phenotype) 1, 2
• Penetrating trauma, especially injection drug use 1, 2
• Documented MRSA colonization elsewhere 1, 2
• Systemic toxicity: fever, hypotension, altered mental status, or SIRS criteria 1, 2

Oral MRSA-Active Options:

When dual coverage for both MRSA and streptococci is needed:

• Clindamycin 300-450 mg orally three times daily (covers both pathogens as monotherapy) 4, 1, 6, 2
• Linezolid 600 mg orally twice daily (covers both pathogens but more expensive) 4, 6, 2

When MRSA coverage is needed but streptococcal activity is uncertain (must combine with β-lactam):

• TMP-SMX 1-2 double-strength tablets orally twice daily PLUS amoxicillin or cephalexin (TMP-SMX lacks reliable streptococcal activity) 1, 6, 2
• Doxycycline 100 mg orally twice daily PLUS a β-lactam (doxycycline lacks reliable streptococcal activity) 4, 1, 6, 2
• Minocycline 100 mg orally twice daily PLUS a β-lactam 4, 6

A retrospective study in a high MRSA-prevalence area found TMP-SMX had significantly higher success rates than cephalexin (91% vs 74%, P<0.001), but this reflects a population with high rates of purulent infection 7. For typical non-purulent cellulitis, β-lactams remain first-line 1, 3.

Critical Dosing Considerations

Weight-based dosing matters for treatment success:

• Inadequate dosing of clindamycin (<10 mg/kg/day) or TMP-SMX (<5 mg TMP/kg/day) is independently associated with clinical failure (OR 2.01, P=0.032) 8
• For obese patients or those with moderate-to-severe cellulitis, ensure adequate weight-based dosing of MRSA-active agents 8

Monitoring and Reassessment

• Reassess at 48-72 hours to confirm improvement (reduction in erythema, swelling, tenderness) 2
• If no improvement by day 5, switch to MRSA-active therapy and consider imaging to exclude abscess or deeper infection 2
• Elevate the affected area to accelerate improvement by facilitating drainage of edema 1, 2

Common Pitfalls to Avoid

• Never use TMP-SMX or doxycycline as monotherapy for non-purulent cellulitis—they lack reliable streptococcal coverage and must be combined with a β-lactam 1, 6, 2
• Do not add rifampin as adjunctive therapy; it provides no benefit and promotes resistance 1, 2
• Do not extend antibiotics beyond 5 days in patients who are clinically improving; this constitutes overtreatment 5, 2
• Do not routinely order blood cultures or imaging for typical outpatient cellulitis; reserve these for severe systemic features, immunosuppression, or atypical exposures 2
• Beware of clindamycin resistance: use only if local resistance rates are <10% 6
• In pregnancy: avoid TMP-SMX in third trimester and tetracyclines throughout pregnancy 2
• In children <8 years: avoid tetracyclines 4, 2
• In elderly patients on ACE inhibitors or with renal insufficiency: TMP-SMX increases hyperkalemia risk 2

Special Considerations

• Address predisposing factors to prevent recurrence: treat tinea pedis, manage lymphedema/venous insufficiency, optimize wound care 1, 2
• For recurrent cellulitis: consider prophylactic penicillin or erythromycin after addressing underlying risk factors 1